HLA-A2限制性CTL表位HPV18E7_(7-15)分子修饰的实验研究  

Experimental study on molecular modification of the CTL epitope HPV18E7_(7-15) restricted by HLA-A2

作　　者：邵笑红[1,2] 欧荣英[1,2] 徐云升[1,2] 张学奇[1,2] 蔡剑峰[1,2] 李秉煦[1,2] 

机构地区：[1]温州医学院附属第一医院皮肤性病科 [2]温州医学院皮肤性病学研究所,浙江温州325000

出　　处：《中国艾滋病性病》2010年第1期7-9,共3页Chinese Journal of Aids & STD

基　　金：国家自然科学基金(编号:30500537;30972800)~~

摘　　要：目的对人类白细胞抗原A2分子(HLA-A2)限制性细胞毒性T淋巴细胞(CTL)表位HPV18E77-15进行氨基酸置换修饰,并探讨修饰后多肽的免疫原性。方法根据量化模体方案,比较置换后的多肽与HLA-A2分子的结合系数,采用标准Fmoc方案合成并纯化多肽、细胞毒实验(51Cr释放法),观察多肽是否能够诱导特异性CTLs。结果修饰肽TLQDIVLHV符合HLA-A2分子限制性细胞毒性T细胞的表位要求,具有特异性细胞毒性T细胞诱导活性。结论修饰肽TLQDIVLHV具有更好的结合力和较强的抗原性,可以作为高危型人乳头瘤病毒(HPV)感染治疗性肽疫苗分子设计的候选表位。Objective To investigate the immunogenicity of peptide modified by amino acid substitution for the CTL epitope HPV18E77-15 restricted by HLA-A2.Methods The affinity of the substituted peptide was compared by quantitative method.Peptides were synthesized and purified by standard Fmoc assay.51Cr release assay was used to determine their abilities of inducing the generation of specific CTLs.Results The modified peptide TLQDIVLHV met the requirements of HLA-A2-restricted CTL epitopes and had the ability of inducing the generation of specific CTLs.Conclusions The modified peptide TLQDIVLHV has better antigenicity and affinity to HLA-A2,and can be used as one of the HLA-A2-restricted candidate epitopes for therapeutic peptide vaccine against HPV infection.

关 键 词：人乳头状瘤病毒 E7抗原 表位 T淋巴细胞 分子修饰 

分 类 号：R752.53[医药卫生—皮肤病学与性病学]